
Today on Pharmaceutical Processing
WuXi STA constructing manufacturing facility in Middletown, Delaware
The Contract Research, Development and Manufacturing Organization (CRDMO) WuXi STA has begun construction on a site in Middletown, Delaware. The company expects it to be operational in 2025. This 190-acre pharmaceutical manufacturing campus will be the company’s second U.S. site and the first on the East Coast. The site will be based in the Middletown…GSK finalizes Affinivax acquisition
GSK (LSE/NYSE:GSK) has wrapped up its acquisition of the privately-held biopharma Affinivax. Cambridge, Massachusetts–based Affinivax has established a vaccine technology platform known as Multiple Antigen Presentation System (MAPS), designed to elicit a strong B-cell and T-cell immune response. GSK was attracted to Affinivax, given its aim to bolster its portfolio of specialty medicines and vaccines. …Sponsored Content See More >
Regulatory See More >

Ultra Supplement announces recall for undeclared tadalafil
The FDA continues to pressure manufacturers and distributors for selling products with undeclared sildenafil and tadalafil. The agency recently announced that Wilmington Delaware–based Ultra Supplement LLC is voluntarily recalling lot number DAP272109 of Sustango capsules over the presence of tadalafil (Cialis). The company markets the product as a supplement for men. Sustango was available for…
Facility See More >

Astellas to spend $70M on new biotech campus in South San Francisco
Astellas Pharma (TSE: 4503) plans to establish a biotech campus in South San Francisco, California, as the core of its West Coast R&D operations. Located near Genentech and Verily Life Sciences facilities, the site at 480 Forbes Boulevard will consolidate several Astellas business units and functions currently based throughout the San Francisco Bay Area. The…
Supply Chain See More >

U.S. government makes an additional 442,000 monkeypox vaccine doses available
Officials from the U.S. Department of Health and Human Services (HHS) have announced plans to provide up to 442,000 doses of the Jynneos vaccine from Bavarian Nordic A/S (OMX:BAVA) available across the country. In May, Biomedical Advanced Research and Development Authority (BARDA) said it had a contract with Bavarian Nordic worth up to $119 million to convert…
Recalls See More >
Taro Pharmaceuticals announces Type I recall of Taro-zoledronic acid injection
The Canadian division of Taro Pharmaceuticals (NYSE:TARO) has announced a voluntary Type 1 recall of six lots of Taro-zoledronic Acid Injection. Type 1 recalls, according to Health Canada, refer to products that could cause serious adverse health consequences or death. It corresponds to Class 1 recalls from the FDA. Taro Pharmaceutical‘s consumer-level recall covers 5 mg/100…